Novo Nordisk's shares fell 9.3%, wiping out over $30 billion in market value after its experimental heart drug ziltivekimab failed to meet trial goals for reducing major cardiovascular events. Analysts criticized the failure as a missed chance to diversify beyond its weight-loss drugs Ozempic and Wegovy, potentially losing a $10 billion annual growth opportunity. The company has been expanding its GLP-1 drug market, including launching pill versions, but this setback raises concerns about its reliance on existing products. Novo Nordisk also recently clashed with Eli Lilly over advertising claims related to GLP-1 drugs.
Novo Nordisk announced that its ZEUS phase 3 trial testing ziltivekimab, an IL-6 pathway inhibitor, in over 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation did not reduce major adverse cardiovascul...
Shares of Novo Nordisk fell sharply after the company announced that its late-stage trial for the heart drug ziltivekimab did not significantly reduce major cardiovascular events like heart attack, stroke, or cardiovascular death compared to a placeb...
Novo Resources is set to start a 2,700-metre drilling program at its Tibooburra Gold Project in New South Wales in late September 2026, pending approvals. Pantoro Gold reported solid gold production and cost efficiency at its Norseman mine, with grow...
Novo Resources is advancing exploration at the Tibooburra Gold Project in NSW through a joint venture with Manhattan Gold Corporation. A ~2,700 meter reverse circulation (RC) drilling program is planned to begin in late Q3 2026, focusing on the Clone...
A U.S. judge has allowed parts of a shareholder lawsuit against Novo Nordisk to move forward, alleging the company misled investors about the design and tolerability of its experimental weight-loss drug CagriSema. Investors claim Novo did not fully d...
